{"id":968536,"date":"2026-05-29T06:53:21","date_gmt":"2026-05-29T10:53:21","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/pharvaris-to-present-clinical-data-at-the-eaaci-annual-congress-2026\/"},"modified":"2026-05-29T06:53:21","modified_gmt":"2026-05-29T10:53:21","slug":"pharvaris-to-present-clinical-data-at-the-eaaci-annual-congress-2026","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/pharvaris-to-present-clinical-data-at-the-eaaci-annual-congress-2026\/","title":{"rendered":"Pharvaris to Present Clinical Data at the EAACI Annual Congress 2026"},"content":{"rendered":"<div class=\"mw_release\">\n<p>ZUG, Switzerland, May  29, 2026  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=uIICqmiceZmFaQX1lirebCTPG7oe4vBjVy6xsIVLfDceobJgpZ_tY7mx78nL7PsRmk8WdVi9-ix9SzVxw-X1frJvdx_LOCuk2fnjsuvlCvyO2XymsAlcknAjCGxvSaHUbZ-huIwi0S-0BYQ5J1BGlQYauaL6v1pt5gQrWrljdQ8YYohhEm3oI2ZuriraAvLvrpc3F3-4wiEPgQhmBUrQpkNfui_7ZmVJ5l0GZqYwNtM=\" rel=\"nofollow\" target=\"_blank\">Pharvaris<\/a> (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced the acceptance of one abstract for oral presentation and seven abstracts for flash talk\/poster presentation at the <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=lm_YVmdku5pPvI66FD6HYXGylyCubakQhurTS0-YHtJa87MrrSOYZCdwdzyrcb2pLoMsQygoOhnXH6HJVD9bGSjf8Keg1d2-ZuVbz0jpbi0uS3Jo-QTzfzXw9oA5OvxgidVqFE3n-ipr7525CyMHukQwmLEppiFZ0QPuERvB8ewMm2LzpRJAaceAlXtkXTFtqpRssyk8XcHsQ2hqSpqzvAeCAa46evF_3A42u9XrgoQ=\" rel=\"nofollow\" target=\"_blank\">European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress 2026<\/a>, to be held from June 12-15, 2026, in Istanbul, Turkey.<\/p>\n<p>Details of the presentations are as follows:<\/p>\n<ul type=\"disc\">\n<li>\n          <strong>Title:<\/strong>\u00a0Oral Deucrictibant Immediate-Release Capsule for On-Demand Treatment of Hereditary Angioedema Attacks: End of Progression Results in the Phase 3 RAPIDe-3 Trial<br \/><strong>Presenter:<\/strong>\u00a0Mauro Cancian, M.D., Ph.D.<br \/><strong>Format: <\/strong>Oral Presentation <br \/><strong>Date, time:\u00a0<\/strong>Friday, June 12, 2026, 3:00-4:30 p.m. TRT (8:00-9:30 a.m. EDT)<\/li>\n<\/ul>\n<ul type=\"disc\">\n<li>\n          <strong>Title:<\/strong>\u00a0Clinical Cardiovascular Safety Assessment of Oral Deucrictibant<br \/><strong>Presenter:<\/strong>\u00a0Anne Lesage, Ph.D.<br \/><strong>Format:<\/strong> Poster Presentation <br \/><strong>Date, time:<\/strong>\u00a0Friday, June 12, 2026, 12:00-1:00 p.m. TRT (5:00-6:00 a.m. EDT)<\/li>\n<\/ul>\n<ul type=\"disc\">\n<li>\n          <strong>Title:<\/strong>\u00a0A Clinically Validated Kinin Biomarker Assay to Differentiate Bradykinin-Mediated from Mast Cell-Mediated Angioedema<br \/><strong>Presenter:<\/strong>\u00a0Evangelia Pardali, Ph.D. <br \/><strong>Format: <\/strong>Poster Presentation<br \/><strong>Date, time:\u00a0<\/strong>Friday, June 12, 2026, 12:00-1:00 p.m. TRT (5:00-6:00 a.m. EDT)<\/li>\n<\/ul>\n<ul type=\"disc\">\n<li>\n          <strong>Title:<\/strong>\u00a0Evaluations of Safety Margins and Response to Deucrictibant Extended-Release (XR) Tablet in Combination with Deucrictibant Immediate-Release (IR) Capsule<br \/><strong>Presenter:<\/strong>\u00a0Anne Lesage, Ph.D.<br \/><strong>Format: <\/strong>Poster Presentation <br \/><strong>Date, time:<\/strong>\u00a0Saturday, June 13, 2026, 12:00-1:00 p.m. TRT (5:00-6:00 a.m. EDT)<\/li>\n<\/ul>\n<ul type=\"disc\">\n<li>\n          <strong>Title:<\/strong>\u00a0Oral Deucrictibant Immediate-Release Capsule for On-Demand Treatment of Hereditary Angioedema Attacks: Results of the Phase 3 RAPIDe-3 Trial<br \/><strong>Presenter:<\/strong>\u00a0Philip Li, M.D., FRCP<br \/><strong>Format: <\/strong>Poster Presentation <br \/><strong>Date, time:\u00a0<\/strong>Saturday, June 13, 2026, 12:00-1:00 p.m. TRT (5:00-6:00 a.m. EDT)<\/li>\n<\/ul>\n<ul type=\"disc\">\n<li>\n          <strong>Title:<\/strong>\u00a0RAPIDe-3 Patient Voices: Qualitative Insights from the Phase 3 Study of Oral Deucrictibant for On-Demand Treatment of Hereditary Angioedema Attacks<br \/><strong>Presenter:<\/strong>\u00a0Anna Valerieva, M.D., Ph.D.<br \/><strong>Format: <\/strong>Poster Presentation<br \/><strong>Date, time:\u00a0<\/strong>Saturday, June 13, 2026, 12:00-1:00 p.m. TRT (5:00-6:00 a.m. EDT)<\/li>\n<\/ul>\n<ul type=\"disc\">\n<li>\n          <strong>Title:<\/strong> Results of the Phase 2 CHAPTER-1 Open-Label Extension Study on the Long-Term Safety and Efficacy of Oral Deucrictibant for Prophylaxis in Hereditary Angioedema<br \/><strong>Presenter: <\/strong>Markus Magerl, M.D.<br \/><strong>Format: <\/strong>Flash Talk <br \/><strong>Date, time:<\/strong>\u00a0Saturday, June 13, 2026, 3:00-4:30 p.m. TRT (8:00-9:30 a.m. EDT)<\/li>\n<\/ul>\n<ul type=\"disc\">\n<li>\n          <strong>Title:<\/strong> CHAPTER-1 Open-Label Extension Study: Long-Term Prophylactic Treatment with Oral Deucrictibant Improved Disease Control and Health-Related Quality of Life in Participants with Hereditary Angioedema<br \/><strong>Presenter:<\/strong>\u00a0Markus Magerl, M.D. <br \/><strong>Format: <\/strong>Flash Talk<br \/><strong>Date, time:\u00a0<\/strong>Saturday, June 13, 2026, 3:00-4:30 p.m. TRT (8:00-9:30 a.m. EDT)<\/li>\n<\/ul>\n<p>\n        <br \/>The posters and presentation slides will be made available on the Investors section of the Pharvaris website at the beginning of the respective presentations at:\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=K1zZuEzVB8_fMQIQw0W-HTxJEBf-wDYOomXV0znZktGZW_ea9Fdi66FSaOqLbgbRioJy2qY9beaoR5wA0-_lsb6aEHno1nhVeK46_sR9TCgCysvnMeoaAccxO5xmLs9FVTOb_rbUi6Uigvr5EG_ZMxW9C7aPcQxnhvAyB3cPqDMWgO2VX_0Lrk-XBdNGTa1j\" rel=\"nofollow\" target=\"_blank\">ir.pharvaris.com\/news-events\/events-presentations<\/a>.<\/p>\n<p>\n        <strong>About Pharvaris <\/strong><br \/>\n        <br \/>Pharvaris is a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs in bradykinin-mediated conditions, including all types of bradykinin-mediated angioedema. Pharvaris\u2019 aspiration is to offer therapies with injectable-like efficacy\u2122, a well-tolerated profile, and the convenience of oral administration to prevent and treat bradykinin-mediated angioedema attacks. By delivering on this aspiration, Pharvaris aims to provide a new standard of care in bradykinin-mediated angioedema. Pharvaris is preparing marketing authorization applications for deucrictibant immediate-release capsule as an on-demand treatment of HAE attacks, and a global pivotal Phase 3 study of deucrictibant extended-release tablet for the prevention of HAE attacks (CHAPTER-3) is ongoing with topline data anticipated in the third quarter of 2026. In addition, CREAATE is an ongoing Phase 3 study of deucrictibant for the prophylactic and on-demand treatment of AAE-C1INH attacks. For more information, visit\u202fhttps:\/\/pharvaris.com\/.<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyODMwNyM3NjI2MTkxIzIyMDU5NDc=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/ODZhYjJjMWYtM2NlNS00NTg4LWE2MGItYjk4Y2Q2M2YyNjlmLTEyMTc1MDAtMjAyNi0wNS0yOS1lbg==\/tiny\/Pharvaris-N-V-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\">\n<pre>Contact\r\nMaggie Beller\r\nVice President, Head of Corporate and Investor Communications\r\nmaggie.beller@pharvaris.com<\/pre>\n<\/p><\/div>\n","protected":false},"excerpt":{"rendered":"<p>ZUG, Switzerland, May 29, 2026 (GLOBE NEWSWIRE) &#8212; Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced the acceptance of one abstract for oral presentation and seven abstracts for flash talk\/poster presentation at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress 2026, to be held from June 12-15, 2026, in Istanbul, Turkey. Details of the presentations are as follows: Title:\u00a0Oral Deucrictibant Immediate-Release Capsule for On-Demand Treatment of Hereditary Angioedema Attacks: End of Progression Results in the Phase 3 RAPIDe-3 TrialPresenter:\u00a0Mauro Cancian, M.D., Ph.D.Format: Oral Presentation &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/pharvaris-to-present-clinical-data-at-the-eaaci-annual-congress-2026\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Pharvaris to Present Clinical Data at the EAACI Annual Congress 2026&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-968536","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Pharvaris to Present Clinical Data at the EAACI Annual Congress 2026 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/pharvaris-to-present-clinical-data-at-the-eaaci-annual-congress-2026\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pharvaris to Present Clinical Data at the EAACI Annual Congress 2026 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"ZUG, Switzerland, May 29, 2026 (GLOBE NEWSWIRE) &#8212; Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced the acceptance of one abstract for oral presentation and seven abstracts for flash talk\/poster presentation at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress 2026, to be held from June 12-15, 2026, in Istanbul, Turkey. Details of the presentations are as follows: Title:\u00a0Oral Deucrictibant Immediate-Release Capsule for On-Demand Treatment of Hereditary Angioedema Attacks: End of Progression Results in the Phase 3 RAPIDe-3 TrialPresenter:\u00a0Mauro Cancian, M.D., Ph.D.Format: Oral Presentation &hellip; Continue reading &quot;Pharvaris to Present Clinical Data at the EAACI Annual Congress 2026&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/pharvaris-to-present-clinical-data-at-the-eaaci-annual-congress-2026\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-29T10:53:21+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyODMwNyM3NjI2MTkxIzIyMDU5NDc=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pharvaris-to-present-clinical-data-at-the-eaaci-annual-congress-2026\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pharvaris-to-present-clinical-data-at-the-eaaci-annual-congress-2026\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Pharvaris to Present Clinical Data at the EAACI Annual Congress 2026\",\"datePublished\":\"2026-05-29T10:53:21+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pharvaris-to-present-clinical-data-at-the-eaaci-annual-congress-2026\\\/\"},\"wordCount\":587,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pharvaris-to-present-clinical-data-at-the-eaaci-annual-congress-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcyODMwNyM3NjI2MTkxIzIyMDU5NDc=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pharvaris-to-present-clinical-data-at-the-eaaci-annual-congress-2026\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pharvaris-to-present-clinical-data-at-the-eaaci-annual-congress-2026\\\/\",\"name\":\"Pharvaris to Present Clinical Data at the EAACI Annual Congress 2026 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pharvaris-to-present-clinical-data-at-the-eaaci-annual-congress-2026\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pharvaris-to-present-clinical-data-at-the-eaaci-annual-congress-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcyODMwNyM3NjI2MTkxIzIyMDU5NDc=\",\"datePublished\":\"2026-05-29T10:53:21+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pharvaris-to-present-clinical-data-at-the-eaaci-annual-congress-2026\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pharvaris-to-present-clinical-data-at-the-eaaci-annual-congress-2026\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pharvaris-to-present-clinical-data-at-the-eaaci-annual-congress-2026\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcyODMwNyM3NjI2MTkxIzIyMDU5NDc=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcyODMwNyM3NjI2MTkxIzIyMDU5NDc=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pharvaris-to-present-clinical-data-at-the-eaaci-annual-congress-2026\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Pharvaris to Present Clinical Data at the EAACI Annual Congress 2026\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Pharvaris to Present Clinical Data at the EAACI Annual Congress 2026 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/pharvaris-to-present-clinical-data-at-the-eaaci-annual-congress-2026\/","og_locale":"en_US","og_type":"article","og_title":"Pharvaris to Present Clinical Data at the EAACI Annual Congress 2026 - Market Newsdesk","og_description":"ZUG, Switzerland, May 29, 2026 (GLOBE NEWSWIRE) &#8212; Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced the acceptance of one abstract for oral presentation and seven abstracts for flash talk\/poster presentation at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress 2026, to be held from June 12-15, 2026, in Istanbul, Turkey. Details of the presentations are as follows: Title:\u00a0Oral Deucrictibant Immediate-Release Capsule for On-Demand Treatment of Hereditary Angioedema Attacks: End of Progression Results in the Phase 3 RAPIDe-3 TrialPresenter:\u00a0Mauro Cancian, M.D., Ph.D.Format: Oral Presentation &hellip; Continue reading \"Pharvaris to Present Clinical Data at the EAACI Annual Congress 2026\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/pharvaris-to-present-clinical-data-at-the-eaaci-annual-congress-2026\/","og_site_name":"Market Newsdesk","article_published_time":"2026-05-29T10:53:21+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyODMwNyM3NjI2MTkxIzIyMDU5NDc=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pharvaris-to-present-clinical-data-at-the-eaaci-annual-congress-2026\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pharvaris-to-present-clinical-data-at-the-eaaci-annual-congress-2026\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Pharvaris to Present Clinical Data at the EAACI Annual Congress 2026","datePublished":"2026-05-29T10:53:21+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pharvaris-to-present-clinical-data-at-the-eaaci-annual-congress-2026\/"},"wordCount":587,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pharvaris-to-present-clinical-data-at-the-eaaci-annual-congress-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyODMwNyM3NjI2MTkxIzIyMDU5NDc=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pharvaris-to-present-clinical-data-at-the-eaaci-annual-congress-2026\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/pharvaris-to-present-clinical-data-at-the-eaaci-annual-congress-2026\/","name":"Pharvaris to Present Clinical Data at the EAACI Annual Congress 2026 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pharvaris-to-present-clinical-data-at-the-eaaci-annual-congress-2026\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pharvaris-to-present-clinical-data-at-the-eaaci-annual-congress-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyODMwNyM3NjI2MTkxIzIyMDU5NDc=","datePublished":"2026-05-29T10:53:21+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pharvaris-to-present-clinical-data-at-the-eaaci-annual-congress-2026\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/pharvaris-to-present-clinical-data-at-the-eaaci-annual-congress-2026\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pharvaris-to-present-clinical-data-at-the-eaaci-annual-congress-2026\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyODMwNyM3NjI2MTkxIzIyMDU5NDc=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyODMwNyM3NjI2MTkxIzIyMDU5NDc="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pharvaris-to-present-clinical-data-at-the-eaaci-annual-congress-2026\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Pharvaris to Present Clinical Data at the EAACI Annual Congress 2026"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/968536","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=968536"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/968536\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=968536"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=968536"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=968536"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}